Beyond by Whoosh Wellness

The consultation is a questionnaire, not an appointment. There is no required video or phone visit and no physical examination. Whoosh’s terms of service put it plainly: using the service means consenting to care “which may include asynchronous communication such as questionnaires, messaging, or other non-real-time interactions,” and acknowledging “the inability to perform a physical examination.”

Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed. A compounding pharmacy prepares them against an individual prescription, which is a different regulatory status from an FDA-approved drug and a different thing again from the research-use-only material sold by the vendors listed under Verified Vendors. Nothing on this page is medical advice, and nothing here says any protocol is appropriate for any particular reader — that is what the prescriber review is for.

1. An online questionnaire. Goals, lifestyle and medical history, submitted through a form. Whoosh’s how-it-works page says it takes about five minutes.
2. A prescriber reviews it. A protocol is prescribed only if the reviewing prescriber judges one appropriate; if not, there is no charge for medication. Beyond describes the reviewer as a board-certified physician conducting an individual review with “no blanket approvals” — that characterisation is Beyond’s, on its About page, and PP has read no licence or credential for any prescriber.
3. A pharmacy dispenses and ships. The protocol is compounded to order at a licensed US compounding pharmacy and cold-shipped to your door, ready to use.

Timings are Whoosh’s, not ours. The figures published on whooshwellness.com are that most reviews complete within one to two hours, that most patients hear back within twenty-four hours, and that orders typically arrive within three days. They appear on Whoosh’s site rather than Beyond’s, and PP has not timed any of them.

Supplies, in the box

Syringes, alcohol swipes and a step-by-step injection guide ship with the first order. Nothing has to be sourced separately.

Nothing to reconstitute

Protocols ship as ready-to-use sterile solution, cold-shipped — no vials to mix, no bacteriostatic water, no reconstitution kit.

Shipping included

Whoosh's pricing page states that all plan prices include physician review, supplies and free shipping, and that monthly refills are automatic.

No charge unless prescribed

You are billed for medication only if a physician approves the prescription. If you do not qualify, you pay nothing for it.

HSA and FSA

Whoosh's pages state that most protocols qualify for HSA and FSA payment. That is their statement about their own billing, not something PP has tested.

Cancelling

Plans auto-renew. They can be cancelled, but only before the next renewal date — both halves of that are in Whoosh's terms, and a renewal that has already billed is not addressed there.

Ongoing contact, described two different ways. Beyond’s About page says monthly check-ins; its product pages say unlimited check-ins and 24/7 ongoing care, and Whoosh’s pricing page says monthly check-ins available 24/7. Those are not the same promise, and PP is not going to pick one — both are on their pages today.

On the compounding itself, Beyond states that its pharmacy partners are PCAB accredited and compound to USP 795 and 797 standards, and that every batch is third-party tested for potency and purity. Those are Beyond’s claims on its About page. No pharmacy is named, no laboratory is named, and no certificate is published, so there is nothing for PP to open and check. Beyond’s FAQ says prescriptions are filled by a licensed 503A compounding pharmacy; its About page and Whoosh’s pages say 503A/503B. Those two statements disagree, and the difference matters — FDA applies current good manufacturing practice requirements to 503B outsourcing facilities and not to 503A pharmacies.

The tile price is not a monthly price. Beyond’s category tiles advertise “Starting as low as $X/mo.” On every page we checked, that figure is the 6-month plan total divided by six: BPC-157 Injection’s tile reads $158/mo against a $949 6-month plan, and $949 ÷ 6 = $158.17. The one-month plan for that protocol is $199. The arithmetic is ours; the numbers are theirs.

Three things we found and did not reconcile. The Lean Bulk Stack page publishes a 1-month and a 3-month plan and no 6-month plan, so its 6-month cell is empty rather than calculated. The Tesamorelin Injection tile reads $158/mo while that page’s own 6-month plan is $1,099, which is $183.17 a month — the tile and the plan grid on the same page disagree. And Beyond serves two Tesamorelin Injection product pages with identical prices, at /products/tesamorelin-injection and /products/tesamorelin-injection1; the protocol is listed once here.

Prices are Beyond’s and change without notice to us. The date above is the date PP read them, not a promise about today.

We may earn a referral fee from healthcare provider links on this page.

Where the compounds stand with FDA. FDA keeps categories for bulk drug substances nominated for use in 503A compounding. Ipamorelin acetate (under the 503B policy) and kisspeptin-10 (under 503A) were placed in Category 2 on 29 September 2023. The nominations for BPC-157, CJC-1295, injectable GHK-Cu, epitalon, TB-500, semax, selank, KPV, MOTS-c and DSIP were withdrawn by the nominators — which is not a softer position than Category 2, because FDA gives Category 2 and Category 3 the same sentence, that it “would consider taking action” under its general enforcement policies, and only Category 1 carries a stated no-action policy. Non-injectable GHK-Cu is in Category 1. Tesamorelin and sermorelin have no listing determination or categorisation at all. A Pharmacy Compounding Advisory Committee meeting on 23–24 July 2026 was scheduled to discuss several of these, so this may have moved.

The two GLP-1 protocols sit in a changed landscape. FDA determined the tirzepatide injection shortage resolved on 19 December 2024 and the semaglutide injection shortage resolved on 21 February 2025, and the period of enforcement discretion for 503A compounding of semaglutide ended on 28 April 2025. FDA states that when a shortage is resolved it generally considers the drug commercially available, and section 503A restricts compounding drugs that are essentially copies of a commercially available drug product. PP draws no conclusion from that — whether a given preparation is essentially a copy turns on a prescriber’s determination that PP cannot see, and FDA uses no prohibition language about it. It is reported here because the dates are public and material. Separately, FDA states that retatrutide and cagrilintide “cannot be used in compounding under federal law”; Beyond lists neither.

We state the code and the rate and nothing more. We do not claim where the code appears on Beyond’s own site, because we searched their pages and found it stated nowhere publicly — no banner, no coupon page, no mention of a 15% rate. What the code applies to, what it excludes and whether it stacks with anything are Beyond’s to decide and are not published anywhere we could read.

• The link on this page goes where it says. Every button here points at Prof. Peptide’s own redirect, /go/whoosh. Requested directly, it returns a 302 whose destination is the affiliate URL byte-for-byte, and following that lands on beyondww.com. PP adds no parameters of its own to it, and a build check refuses any link on this page that points anywhere else.
• Every price came off the protocol’s own product page. All 21 product pages on beyondww.com were read, and each 1-month, 3-month and 6-month figure in the table above is the plan total published on that protocol’s page, with one row per variant Beyond sells. Nothing is averaged, converted or carried over from a sibling product.
• The tile figure is the 6-month total divided by six. Checked against every page that shows one: BPC-157 Injection’s tile reads $158/mo against a $949 6-month plan, and $949 ÷ 6 = $158.17. The numbers are Beyond’s and the arithmetic is ours — which is how we know the tile is not the price of a one-month plan.
• The catalogue is 21 product pages, and two of them are the same protocol. Reading all of them is also what surfaced the three things the prices section reports: the Lean Bulk Stack page publishes no 6-month plan, the Tesamorelin Injection tile disagrees with that page’s own plan grid, and Beyond serves the Tesamorelin Injection product at two separate URLs.
• PROFPEPTIDE15 is the code carried by the link we publish. It forms the path of the destination URL, and that URL resolves. What we did not do is put an order through: the 15% off is Beyond’s to apply, we have not seen it applied at a checkout, and we found the code stated nowhere public on Beyond’s own site.
• The legal documents resolve — on a different domain. beyondww.com/terms and beyondww.com/privacy both return 404. The footer’s Terms of Service and Privacy Policy links point instead at whooshwellness.com, where both pages load and are presented as Whoosh Wellness’s. That is the readable connection between the two names, and PP reports it as those documents present it without making any statement about who owns or operates either site.

What is not there to check. No prescriber, medical director or compounding pharmacy is named anywhere on either site — Whoosh’s own footer links an “Our Team” page that returns a 404. No certificate of analysis is published, and no testing laboratory is named, so there is no document to open. No list of the states served is published. No refund policy is published. And Beyond links a LegitScript search for whooshwellness.com whose result our request was blocked from reading, so PP publishes no certification status either way.